{
  "id": 7955419,
  "title": "Pakistan’s Ferozsons to manufacture US-based Gilead's HIV prevention drug",
  "url": "https://urgent.news/2026/09/17/pakistans-ferozsons-to-manufacture-us-based-gileads-hiv-prevention",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T05:11:06.000Z",
  "source": {
    "name": "Business Recorder",
    "slug": "business-recorder",
    "url": "https://www.brecorder.com/news/40439920/pakistans-ferozsons-to-manufacture-us-based-gileads-hiv-prevention-drug"
  },
  "original_language": "en",
  "account": "Pakistani pharmaceutical company Ferozsons Laboratories Limited (FEROZ) has entered into an expanded royalty-free licensing agreement with US-based Gilead Sciences for the production of their investigational HIV prevention drug, lenacapavir. The agreement covers 120 high-incidence countries, primarily low- and lower-middle income nations. This move will support manufacturing readiness, technology transfer, and future supply planning during the ongoing Phase 3 PURPOSE 365 trial. If the once-yearly lenacapavir is approved, it could offer a full year of HIV prevention with a single dose, expanding prevention options and addressing barriers to pre-exposure prophylaxis (PrEP) uptake and persistence. Ferozsons will manufacture the injectable drug at its JV subsidiary, BF Biosciences Limited, while selling the oral variant directly.",
  "summary": "Ferozsons Laboratories Limited (FEROZ), a Pakistani pharmaceutical company, has joined a select group of global manufacturers in Gilead Sciences’ expanded royalty-free licensing programme for its investigational once-yearly lenacapavir for HIV prevention, covering 120 high-incidence countries. The listed pharma disclosed the development in a notice to the Pakistan Stock Exchange (PSX) on…",
  "key_points": [
    "Ferozsons Laboratories signs expanded licensing deal with Gilead Sciences.",
    "Agreement covers 120 high-incidence countries, supports manufacturing and supply.",
    "Ferozsons to manufacture injectable lenacapavir, sell oral variant directly."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}